Drug Type Small molecule drug |
Synonyms |
Target |
Action antagonists |
Mechanism ETA antagonists(Endothelin receptor type A antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glomerulonephritis, IGA | Phase 3 | China | 03 Jan 2025 | |
Proteinuria | Phase 3 | China | 03 Jan 2025 | |
Albuminuria | Phase 2 | China | 23 May 2023 | |
Chronic Kidney Diseases | Phase 2 | China | 23 May 2023 | |
Diabetic Nephropathies | Phase 2 | China | 23 May 2023 | |
Pulmonary Arterial Hypertension | Discovery | China | 16 Dec 2020 |
Phase 2 | - | (hidsyneiqj) = SC0062 significantly reduced proteinuria in the high-dose group (20mg) compared to the placebo group. esjfhzttrn (saohabwxgm ) Met View more | Positive | 25 Feb 2025 | |||
Placebo | |||||||
Phase 2 | 131 | SC0062 5 mg | (nsguevxvqz) = avlmvljtnf kstouqjrjz (kzxzddjktj ) Met View more | Positive | 04 Nov 2024 | ||
SC0062 10 mg | (nsguevxvqz) = bdpdndctcn kstouqjrjz (kzxzddjktj ) Met View more | ||||||
Phase 2 | - | (yvidntasai) = SC0062 resulted in a clinically meaningful and statistically significant reduction in proteinuria qfscqdbyha (iardtjbuup ) Met View more | Positive | 08 Jul 2024 | |||
Placebo | |||||||
CTR20201868 (Literature) Manual | Phase 1 | - | - | (sxurwbfzfz) = Single doses of 10 to 100 mg and multiple daily doses of 20 and 50 mg for 6 days were well tolerated. muxvywxsld (pkulosxqdp ) | Positive | 07 Mar 2024 |